2026-03-09 · 个股论点

分析$HIMS全球用户变现潜力，类比$HOOD/$META，建议做多。

中文翻译

感觉大家没有正确阐述 $HIMS 的多头逻辑：这是我的观点。 $HIMS 的主要护城河是零售受众的网络捕获。而多头逻辑在于潜在收入的货币化。 $HOOD 在 2025 年的金融科技领域实现了同样的效果。 $META（完全成熟后）在过去十年的社交媒体领域也实现了同样的效果。 $HIMS 现在正处于 2026 年的起点。但鉴于 Zava + Eucalyptus 带来了全球（欧洲、澳大利亚、日本、加拿大）数百万新用户： $HIMS 现在在医疗领域拥有了独一无二的零售受众捕获能力。然而，与市值约 700 亿美元的 Robinhood 和 1.6 万亿美元的 $META 巨头不同的是：它们已经通过利润率优化和新收入流成功货币化了其零售受众。而且非常激进。$HIMS 尚未做到。 Robinhood 通过推出银行/信用卡/预测市场等新产品做到了这一点。现在这些新产品各自独立产生超过 1 亿美元的新收入流。 $META 通过收购 WhatsApp/Instagram 后最大化捕获每用户收入做到了这一点。然而，$HIMS 尚未像在美国那样（例如睾酮疗法）获得同样的机会。部分原因是之前的诉讼。现在这些障碍已清除，多头逻辑再次显现：与其建模 Zava/Eucalyptus 传统带来的收入，重要的是关注通过人数实现的零售网络捕获。因为这是最大的潜在收入来源 + 未被定价的收入预测超预期。现在，十亿美元的问题是： $HIMS 最终会像 $HOOD 吗？ $HIMS 现在拥有医疗领域最大的零售网络 + 分销渠道之一。然而，与金融科技或社交媒体渠道相比，医疗领域的交叉销售似乎更难。它最终是成为 3000 亿美元公司还是 500 亿美元公司，取决于管理层能否解决这一问题。因此，对于旁观者来说，如果 $HIMS 能够设法从新的全球用户群中实现潜在收入扩张，再次做多可能值得。~40%+ 的做空比例和新的 $NVO 合作也是巨大的加分项。

英文原文

Feels like people aren't articulating the bull case for $HIMS correctly: Here's my view. The main moat of $HIMS is network capture of retail audiences. And the bull case is latent revenue monetization. $HOOD achieved that same effect in fintech over 2025. $META (fully grown) achieved that same effect in the social media sector over the past decade. $HIMS is now at the starting point in 2026. But given millions of new users across the globe (Europe, Australia, Japan, Canada) from Zava + Eucalyptus: $HIMS now has that one-of-a-kind retail audience capture in the healthcare sector. However, the difference between ~$70B companies in Robinhood and $1.6T giants in $META is that: They've already successfully monetized their retail audiences both through margin optimization, and new revenue streams. And very aggressively. $HIMS has not yet. Robinhood did so by pushing new products from banking/credit cards/prediction markets/etc. And they are all now independently generating $100m+ each as new revenue streams. $META did so by capturing the maximum amount of revenue per user after acquiring WhatsApp/Instagram. However, $HIMS has not gotten the chance to yet in the same way they did with the US (eg. Testosterone). Especially partially due to former lawsuits. Now that's cleared up, the bull case can be seen again: Instead of modeling what revenue Zava/Eucalyptus traditionally brought, the important thing to look at is retail network capture through # of people. As this is biggest source of latent revenue + revenue projection beats not priced in. Now, the billion dollar question is: Will $HIMS end up like $HOOD? $HIMS now has the one of the largest retail networks + distribution for healthcare. However, cross-selling seems much harder in healthcare vs. fintech or social media channels. The answer whether it ends up a $30B company or a $5B one is up for management to figure out. So for people on the sideline, it might be worth flipping long again in the off-chance $HIMS manages to figure out latent revenue expansion from their new global userbase. The ~40%+ short interest and the new $NVO partnership serves as a huge bonus as well.

在 X 上查看原推 ↗